University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...

A Belfast woman with terminal cancer says the “voices of everyone affected by ovarian cancer in Northern Ireland must be ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Preparations Underway for Phase 3 Ovarian Cancer Trial; Set to Initiate in 1Q25 Imunon, Inc. (NASDAQ:IMNN) previously reported positive topline ...

Penn Ovarian Cancer Research Center and Basser Center for BRCA, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States ...

These old drugs in a new regime will be a useful salvage." Sir Paul Nurse, director general of Imperial Cancer Research Fund, said: "We've been waiting for good news on ovarian cancer for some ...

The University of Iowa has been selected among 22 other research teams to participate in the Advanced Research Projects ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 ...

Fresh from news of a “complete response” from other clinical trials last week, Imugene has now dosed the first patient with a ...

While Monday’s trading session was a win for CERo shareholders, the stock’s year-to-date (YTD) performance paints a more complex picture. As of today, CERO is down by a staggering -98.59% YTD, which ...